Autolus Therapeutics plc.
AUTL.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for the treatment of cancer. The company designs, develops, and manufactures advanced cell therapies, primarily Chimeric Antigen Receptor (CAR) T-cell therapies, targeting va...Show More
Better Health for All
0
No evidence available to assess Autolus Therapeutics plc on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Autolus Therapeutics plc on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
20
The company's CEO to median employee pay ratio was 13.17:1 in 2023.
1
The median gender pay gap for UK employees was 7.96% in 2024, meaning women earned 92.04% of men's median pay.
2
An employee engagement survey in 2024 had a 79% response rate, and 89% of employees highly or strongly agreed that the company's mission makes their job feel important.
3
The voluntary attrition rate for 2024 was 9.6%.
4
There is no public record of labor-law breaches or human rights violations.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Autolus Therapeutics plc on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-10
Autolus has a formal whistleblower policy with a 24/7 toll-free compliance hotline and website, operated by an independent third-party provider.
1
The policy prohibits retaliation against individuals reporting concerns in good faith, and contact is kept strictly confidential.
2
The company has had zero financial restatements in the past five years. Approximately 60% of its board members are independent, and related party transactions require Audit Committee approval.
3
Autolus has a comprehensive anti-corruption policy that requires compliance with laws like the U.K. Bribery Act and U.S. Foreign Corrupt Practices Act, prohibiting direct or indirect payments to foreign officials.
4
However, the effectiveness of its anti-corruption training is not publicly measured. The ethics hotline, which handles various compliance concerns, is operated by an independent third-party provider, but the extent of independent verification for other ethical claims is not specified.
5
Kind to Animals
0
No specific, concrete data points were found across the provided articles to score any of the KPIs for Autolus Therapeutics plc against the 'Kind to Animals' value. While multiple articles state that the company conducts pre-clinical trials on animals, this fact alone does not provide the quantitative or qualitative detail required by any specific KPI in the rubric, such as the volume of animals used, the details of an animal testing policy, or investment in alternatives.
1
Therefore, all KPIs are omitted due to lack of direct evidence.
No War, No Weapons
0
No evidence available to assess Autolus Therapeutics plc on No War, No Weapons.
Planet-Friendly Business
-50
Autolus Therapeutics plc reported total Scope 1, 2, and 3 greenhouse gas emissions of 2,557.7 tCO₂e in 2023, an increase from 930.5 tCO₂e in 2022.
1
The company sources 37% of its operational energy consumption from renewables as of 2023.
2
Autolus is seeking BREEAM EXCELLENT certification for its Nucleus facility, but no facilities are currently certified.
3
The company achieved a waste diversion rate of 62% in 2023.
4
Autolus conducts environmental impact assessments quarterly as of 2023.
5
The company does not have SBTi-validated targets, but a sustainability strategy is being considered.
6
Autolus has an ISO 14001 environmental management system certification and achieved 98% third-party environmental audit compliance in 2023, with no annual environmental compliance violations reported.
7
Respect for Cultures & Communities
0
Autolus Therapeutics has no reported cultural appropriation incidents.
1
The company's business model, focused on biopharmaceutical development, does not typically involve activities that would lead to cultural appropriation concerns, nor does it inherently require formal partnerships with indigenous or local community groups, cultural impact assessment protocols, or FPIC processes.
2
The company's operations do not appear to impact cultural or heritage sites, and there is no specific community representation on governance bodies.
3
While Autolus states it makes efforts to be a responsible member of the communities in which it works, there is no documented social license to operate.
4
Safe & Smart Tech
0
The company has no documented data breaches.
1
It obtained ISO 27001 certification for its information security management systems in February 2025.
2
Employees and contractors receive periodic security training, including simulated intrusion attempts, and are required to certify compliance, but no completion rates or effectiveness metrics are provided.
3
The company states it is not aware of any material risks from cybersecurity threats.
4
It conducts vulnerability assessments and penetration testing.
5
The company is committed to safeguarding personal information in line with applicable laws, including GDPR and UK GDPR.
6
It has a privacy notice outlining user rights such as access, update, deletion, and objection to processing.
7
Data from CCTV is retained for 60 days unless required for law enforcement.
8
The email alert form only asks for an email address.
9
The company previously identified a material weakness in its internal control over financial reporting related to its financial statement closing process, which it is taking steps to remediate.
10
Zero Waste & Sustainable Products
-10
Autolus Therapeutics plc's Nucleus manufacturing site achieves 100% diversion of waste from landfill.
1
The company's sustainable packaging materials constitute 65% of its packaging.
2
Autolus has implemented waste reduction initiatives at its Nucleus manufacturing site, including using more environmentally friendly cleaning materials in non-GMP areas, and has achieved a 43% reduction in biohazard waste.
3